Page last updated: 2024-12-10

[4-(benzenesulfonyl)-1-piperazinyl]-(1-piperidinyl)methanone

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

You're describing a chemical compound with a rather complex name, but it's actually a known molecule with a more straightforward chemical structure and name: **Benzylsulfonylpiperazine-piperidinone**, or **BSPP** for short.

**Structure:**

* **Benzylsulfonylpiperazine:** This part refers to a piperazine ring (a six-membered ring with two nitrogen atoms) that has a benzenesulfonyl group (a benzene ring attached to a sulfur atom and two oxygen atoms) attached to one of its nitrogen atoms.
* **Piperidinone:** This part indicates a piperidine ring (a six-membered ring with one nitrogen atom) with a carbonyl group (C=O) attached to it.

**Chemical formula:** C16H23N3O3S

**Importance in Research:**

BSPP has been studied extensively for its potential pharmacological activity. It has shown:

* **Antioxidant activity:** BSPP has been found to scavenge free radicals, which are highly reactive molecules that can damage cells and contribute to diseases like cancer and aging.
* **Anti-inflammatory activity:** BSPP has demonstrated the ability to reduce inflammation in various models, potentially making it useful in treating conditions like arthritis.
* **Anti-cancer activity:** Studies have shown that BSPP can inhibit the growth of cancer cells and even induce their death, suggesting its potential in cancer treatment.

**However, it's crucial to note:**

* **Preclinical research:** Most of the studies on BSPP's effects have been conducted in laboratory settings and animal models. These results don't necessarily translate directly to humans.
* **Further research:** More research is needed to determine the safety and efficacy of BSPP for human use.

**In summary:** BSPP is a promising molecule with a range of potential pharmacological properties, particularly in the areas of antioxidants, anti-inflammatories, and anti-cancer agents. More research is needed to fully understand its potential benefits and risks.

Cross-References

ID SourceID
PubMed CID2929432
CHEMBL ID1587240
CHEBI ID123284

Synonyms (24)

Synonym
OPREA1_703906
OPREA1_310365
MLS001167155 ,
smr000641043
CHEBI:123284
AKOS000602828
[4-(phenylsulfonyl)piperazin-1-yl](piperidin-1-yl)methanone
STK927461
[4-(benzenesulfonyl)piperazin-1-yl]-piperidin-1-ylmethanone
HMS2952H23
510734-50-6
F1243-0125
(4-(phenylsulfonyl)piperazin-1-yl)(piperidin-1-yl)methanone
Z237911276
CHEMBL1587240
(4-besylpiperazino)-piperidino-methanone
cid_2929432
bdbm64198
[4-(benzenesulfonyl)-1-piperazinyl]-(1-piperidinyl)methanone
[4-(phenylsulfonyl)piperazin-1-yl]-piperidin-1-yl-methanone
cambridge id 7179174
Q27212991
SR-01000253616-1
sr-01000253616
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
sulfonamideAn amide of a sulfonic acid RS(=O)2NR'2.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (3)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, Beta-lactamaseEscherichia coli K-12Potency22.38720.044717.8581100.0000AID485294
DNA dC->dU-editing enzyme APOBEC-3F isoform aHomo sapiens (human)Potency35.48130.025911.239831.6228AID602313
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Hsf1 proteinMus musculus (house mouse)EC50 (µMol)32.82600.160024.4900236.5000AID2382
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (7)

Assay IDTitleYearJournalArticle
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).2014Journal of biomolecular screening, Jul, Volume: 19, Issue:6
A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).
AID1159537qHTS screening for TAG (triacylglycerol) accumulators in algae2017Plant physiology, Aug, Volume: 174, Issue:4
Identification and Metabolite Profiling of Chemical Activators of Lipid Accumulation in Green Algae.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (5)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's3 (60.00)24.3611
2020's2 (40.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.94

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.94 (24.57)
Research Supply Index1.79 (2.92)
Research Growth Index4.73 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.94)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other5 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]